<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433586</url>
  </required_header>
  <id_info>
    <org_study_id>2015D006250</org_study_id>
    <secondary_id>K01HL130625</secondary_id>
    <nct_id>NCT03433586</nct_id>
  </id_info>
  <brief_title>COMT on Aspirin Platelets Effects (CAPE)</brief_title>
  <acronym>CAPE</acronym>
  <official_title>COMT on Aspirin Platelets Effects (CAPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim I: Examine the role of genetic variation in COMT on platelet function in a
      blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for
      10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by
      fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and
      GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and
      ADP.

      Specific Aim II: Examine the effects of platelet releasates harvested at the end of each
      treatment arm on angiogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blinded, placebo controlled study. This study is designed to
      detect the variation in platelet function based on COMT variation and how these platelets
      respond to cancerous cells.

      We expect to enroll 100 healthy participants with the intention of studying 90 participants
      to complete the protocol.

      Individuals aged 18 to 40 years will be eligible to participate in this study if they do not
      have history of fainting/problems related to blood draws, major chronic medical illnesses,
      regular or current treatment of Aspirin™.

      Examine the role of genetic variation in in catechol-O-methyltransferase (COMT) on platelet
      function in a randomized double-blinded placebo controlled clinical trial of daily Aspirin™
      (81 mg) versus placebo over 10-14 days. Platelet function will be assessed with a platelet
      aggregometry and by fluorescence-activated cell sorting assessment of platelet adhesion
      molecule GPIIIb/IIIa and p-selectin.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>participants will be randomized to aspirin or placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation</measure>
    <time_frame>At end of treatment 10-14 days the platelets will be activated on the same day as blood collection.</time_frame>
    <description>Platelets will be activated with arachidonic acid, thrombin, collagen, ADP and epinephrine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% expression of P-selectin on resting and activated platelets</measure>
    <time_frame>At end of treatment 10-14 days the platelets will be activated on the same day as blood collection.</time_frame>
    <description>Platelets activated with arachidonic acid, ADP, collagen and epinephrine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (81mg) will be taken orally daily for 10-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>81mg of aspirin for 10+/-3 days</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, 18-40 years

        Exclusion Criteria:

          -  taking aspirin. Smoking, pregnancy, history of cancer of cardiovascular disease.
             Mental illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn T Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn T Hall, PhD</last_name>
    <phone>617 278 0938</phone>
    <email>khall0@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Zaharris</last_name>
    <phone>617 278 0472</phone>
    <email>ezaharris@rics.bwh.harvard.edu</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA, Loscalzo J, Samani NJ, Ridker PM, Kaptchuk TJ, Chasman DI. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2160-7. doi: 10.1161/ATVBAHA.114.303845. Epub 2014 Jul 17.</citation>
    <PMID>25035343</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Kathryn Tayo Hall</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

